3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Colorectal Neoplasms
3
Uveal Melanoma
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Carcinoma, Renal Cell
2
Uterine Cervical Neoplasms
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Small Cell Lung Carcinoma
1
Sarcoma
1
Lung Neoplasms
1
Glioblastoma
1
Fibrolamellar hepatocellular carcinoma
1
Esophageal Squamous Cell Carcinoma
1
Esophageal Neoplasms
1
Central Nervous System Neoplasms
1
Carcinoma, Transitional Cell
1
Carcinoma, Squamous Cell
1
Carcinoma, Non-Small-Cell Lung
1
Carcinoma, Merkel Cell
1
Carcinoma
1
Brain Neoplasms
1
Astrocytoma
1
Adenoma, Islet Cell
1
Interventions
pembrolizumab
88
Carboplatin
77
Specimen Handling
76
Magnetic Resonance Spectroscopy
63
Pemetrexed
59
Cisplatin
47
durvalumab
44
Paclitaxel
38
Nivolumab
34
atezolizumab
32
osimertinib
29
Radiotherapy
29
Radiosurgery
29
Biopsy
26
Blood Specimen Collection
25
Gemcitabine
24
Docetaxel
24
Immunoglobulin G
23
Disulfides
22
Standard of Care
21
Drug Therapy
21
Etoposide
19
Taxes
18
Practice Guidelines as Topic
18
Radiation
17
Educational Status
16
130-nm albumin-bound paclitaxel
15
X-Rays
14
Surveys and Questionnaires
14
Bevacizumab
14
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Lung Neoplasms
×
aflibercept
×
1 year
×
Clear all
NCT00532155
2025-09-10
VITAL
Sanofi
Phase 3
Completed
913 enrolled
16 charts